About this trial
Myopia is one of the most common visual impairments worldwide.This not only poses long-term risks to individual health but also imposes significant medical and economic burdens on society. \[6\] Therefore, delaying the onset of myopia and effectively controlling its progression has become an urgent issue that needs to be addressed.In recent years, a new type of highly aspherical lenslet (HAL) has been proposed. Its optical design includes a refractive correction area in the central region and a peripheral annular area. This annular area can form a "myopic defocus zone", increasing the myopic defocus signal around the retina. Studies have confirmed that this design can effectively slow down the progression of myopia in already myopic children. However, it is currently unclear whether this lens has a preventive effect on children who are not yet myopic but have a risk of developing myopia.
Eligibility criteria
Qualifiers
Children aged 6 to 9 with low hyperopia, regardless of gender
The refractive error is between 0 and 2.00D
The best corrected visual acuity of both eyes is ≥ 0.10 LogMAR
The subjects themselves and their guardians voluntarily participated
Disqualifiers
Systemic diseases or eye diseases
Received myopia control treatment through medication or optical
Any situation where participation is deemed unsuitable by the investigator
Trial design
Treatments tested in this trial
- With-the-Rule Astigmatic Defocus Lens
- With-the-Rule Astigmatic Defocus Lens (Non-plano)
- Single Vision
Treatment groups
Locations
Sponsors and collaborators
He Eye Hospital
Lead sponsor
He Eye Specialist Hospital
Collaborator